The estimated Net Worth of Hunter C Smith is at least $7.36 Milión dollars as of 19 March 2024. Mr. Smith owns over 15,515 units of Rhythm Pharmaceuticals stock worth over $4,829,372 and over the last 9 years he sold RYTM stock worth over $608,498. In addition, he makes $1,922,850 as Chief Financial Officer at Rhythm Pharmaceuticals.
Hunter has made over 20 trades of the Rhythm Pharmaceuticals stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 15,515 units of RYTM stock worth $608,498 on 19 March 2024.
The largest trade he's ever made was exercising 27,026 units of Rhythm Pharmaceuticals stock on 5 December 2023 worth over $185,939. On average, Hunter trades about 2,741 units every 34 days since 2015. As of 19 March 2024 he still owns at least 97,939 units of Rhythm Pharmaceuticals stock.
You can see the complete history of Mr. Smith stock trades at the bottom of the page.
Hunter C. Smith serves as Chief Financial Officer of the Company. Mr. Smith has been Chief Financial Officer since July 2017, Treasurer since August 2017, Interim President and Chief Executive Officer since March 2020 and Secretary since April 2020. He has more than 25 years of global finance and management experience across multiple industries and financial disciplines, including expertise in business analysis and planning, mergers and acquisitions, treasury, capital raising and investor relations. Previously, he was Vice President, Finance and Chief Financial Officer of the Inflammation and Immunology Business Unit at Celgene Corporation, or Celgene, a global biopharmaceutical company, from 2013 to July 2017. In this role, Mr. Smith provided finance leadership for the global launch of Otezla® and led global business planning and analysis for commercial affiliates and clinical study activities in over 16 countries. Before joining Celgene, Mr. Smith worked in roles of increasing responsibility at Bunge Limited from 1999 to 2013, including Director of Investor Relations, Chief Financial Officer—Asia, Chief Risk Officer, Corporate Treasurer, and Chief Financial Officer of Bunge's Sugar and Bioenergy Segment. Until its acquisition by Brookfield Infrastructure Partners in December 2019, Mr. Smith also served as an independent director of Genesee & Wyoming Inc. and is a member of its compensation and governance committees. Mr. Smith holds an M.B.A. in Finance from New York University's Stern School of Business and a B.A. in History from Northwestern University.
As the Chief Financial Officer of Rhythm Pharmaceuticals, the total compensation of Hunter Smith at Rhythm Pharmaceuticals is $1,922,850. There are no executives at Rhythm Pharmaceuticals getting paid more.
Hunter Smith is 52, he's been the Chief Financial Officer of Rhythm Pharmaceuticals since 2020. There are 9 older and 8 younger executives at Rhythm Pharmaceuticals. The oldest executive at Rhythm Pharmaceuticals Inc. is Dr. David P. Meeker M.D., 67, who is the Chairman, Pres & CEO.
Hunter's mailing address filed with the SEC is 222 BERKELEY STREET, 12TH FLOOR, , BOSTON, MA, 02116.
Over the last 13 years, insiders at Rhythm Pharmaceuticals have traded over $83,445,563 worth of Rhythm Pharmaceuticals stock and bought 6,290,000 units worth $106,961,700 . The most active insiders traders include Forest Baskett, Scott D Sandell a Peter J Barris. On average, Rhythm Pharmaceuticals executives and independent directors trade stock every 17 days with the average trade being worth of $3,358,405. The most recent stock trade was executed by Pamela J. Cramer on 9 September 2024, trading 4,099 units of RYTM stock currently worth $77,963.
rhythm pharmaceuticals inc. is a biotechnology company located in 855 boylston street, 11th floor, boston, ma, united states.
Rhythm Pharmaceuticals executives and other stock owners filed with the SEC include: